View More Recent Stories
-
Samsung Bioepis and Biogen (BIIB) Receive Positive CHMP Opinion for Aflibercept Biosimilar, OPUVIZ
-
Biogen (BIIB) Appoints Lloyd B. Minor and Mene Pangalos to its Board
-
BMO Capital Reiterates Outperform Rating on Biogen (BIIB)
-
Biogen (BIIB) Reports Positive Topline Results from Study of Higher Dose Regimen of Nusinersen
-
BMO Capital Reiterates Outperform Rating on Biogen (BIIB)
-
Biogen (BIIB) PT Lowered to $251 at Mizuho
-
Biogen (BIIB) PT Lowered to $302 at Truist Securities
-
Biogen (BIIB) PT Raised to $292 at RBC Capital
-
Midday movers: Meta Platforms, Lilly rise; Arm, Moderna fall
-
Biogen (BIIB) tops Q2 expectations, raises profit guidance
-
Biogen (BIIB) Tops Q2 EPS by 127c; profit guidance raised
-
Biogen (BIIB) Reports New Data Showing Three Years of Continuous Treatment with Dual-Acting LEQEMBI Continues to Significantly Benefit Early Alzheimer's Disease Patients
-
Biogen (BIIB), Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer’s Disease
-
RBC's biotech survey shows investors more bearish vs. last time
-
Biogen (BIIB) PT Lowered to $294 at Baird
-
Eisai slumps 13% as EU regulators reject Alzheimer’s treatment developed with Biogen
-
Goldman Sachs Reiterates Buy Rating on Biogen (BIIB), 'We next await the August 1 earnings call'
-
Midday movers: Bristol-Myers, 3M and Deckers rise; Dexcom falls
-
Biogen (BIIB) PT Lowered to $307 at Piper Sandler
-
Biogen (BIIB) PT Lowered to $282 at RBC Capital
-
Biogen (BIIB): EMA has adopted a negative opinion on MAA of Lecanemab for early Alzheimer’s disease
-
SAGE Therapeutics (SAGE) Falls 24% After Phase 2 KINETIC 2 Study of SAGE-324 Fails
-
SAGE Therapeutics (SAGE) and Biogen (BIIB) Report Topline Results from Phase 2 KINETIC 2 Study of SAGE-324
-
Biogen (BIIB) PT Lowered to $313 at Piper Sandler
-
Biogen: RBC says 'very likely' that Leqembi will be approved in Europe
-
RBC Capital Reiterates Outperform Rating on Biogen (BIIB), very likely Leqembi will be approved in Europe
-
Biogen (BIIB) trades lower after after Lilly's Alzheimer's drug is approved
-
Biogen (BIIB) Completes Acquisition of Human Immunology Biosciences
-
RBC Capital on Biogen (BIIB): 'We See An EU Approval In 3Q24 As Likely'
-
RBC Capital Reiterates Outperform Rating on Biogen (BIIB)
-
Biogen (BIIB) Announces TOFIDENCE Approved in the EU
-
Scotiabank Reiterates Sector Outperform Rating on Biogen (BIIB)
-
Eisai, Biogen (BIIB) announced FDA acceptance of sBLA for LEQEMBI IV maintenance dosing

